Related Experiment Videos
Branched DNA for quantification of viral load
1Chiron Corporation, Emeryville, California 94608, USA.
Immunological Investigations
|January 1, 1997
Summary
This study introduces a branched DNA (bDNA) assay for quantifying nucleic acids, such as HIV RNA, in patient samples. The assay accurately measures viral load across different HIV subtypes, aiding in treatment efficacy and prognosis.
Area of Science:
- Immunology
- Molecular Biology
- Virology
Background:
- Quantifying nucleic acids in patient samples is crucial for disease monitoring and treatment efficacy.
- Existing methods may face challenges in accurately detecting and quantifying viral load across different genetic subtypes.
- Accurate viral load measurement is essential for predicting disease progression and treatment response in viral infections.
Purpose of the Study:
- To evaluate a novel branched DNA (bDNA) signal amplification technology for direct quantification of nucleic acids in patient samples.
- To assess the accuracy and reliability of the bDNA assay in quantifying HIV RNA across diverse HIV-1 genetic subtypes (A-F).
- To explore the utility of the bDNA assay for monitoring viral load in Hepatitis C Virus (HCV) infections and predicting treatment outcomes.
Main Methods:
- A solid-phase nucleic acid hybridization assay utilizing branched DNA (bDNA) signal amplification.
- Detection of HIV RNA involves hybridization with specific oligonucleotides and branched DNA molecules, followed by chemiluminescent detection.
- In vitro RNA transcripts of HIV subtypes A-F were used to validate assay performance across genotypes.
Main Results:
- The bDNA assay demonstrated direct proportionality between signal output and target nucleic acid levels.
- HIV subtypes A-F were quantified within a factor of 1.5, indicating genotype-independent accuracy.
- The assay shows potential for determining viral load in HCV patients, correlating with prognosis and response to alpha-interferon therapy.
Conclusions:
- The bDNA assay provides an accurate and reliable method for quantifying viral load in clinical samples, irrespective of HIV genotype.
- This technology is valuable for monitoring treatment efficacy and predicting patient outcomes in HIV and HCV infections.
- Accurate viral load quantification using bDNA assays can inform clinical decisions regarding patient management and therapeutic strategies.